Search Results for "raloxifene"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for raloxifene. Results 11 to 15 of 15 total matches.
See also: Evista
Romosozumab (Evenity) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
of fracture.
The selective estrogen receptor modulator raloxifene
(Evista; only available generically) can ...
The FDA has approved romosozumab-aqqg (Evenity –
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
Romosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide (Tymlos) and...
Teriparatide (Forteo) for Osteoporosis
The Medical Letter on Drugs and Therapeutics • Feb 03, 2003 (Issue 1149)
& Gamble) 5 mg PO daily 63.22
or 35 mg PO weekly 61.90
SELECTIVE ESTROGEN RECEPTOR MODULATOR
Raloxifene ...
Teriparatide (ter i par' a tide; Forteo - Lilly), a recombinant segment of human parathyroid hormone, has been approved by the FDA for parenteral treatment of osteoporosis in post-menopausal women, and in men with idiopathic or hypogonadal osteoporosis, who are at high risk for fracture. Teriparatide is the first approved treatment for osteoporosis that stimulates bone formation. Other drugs approved for this indication inhibit bone resorption (Treatment Guidelines from the Medical Letter 2002;1:13).
Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
tabs 20-40 mg PO 10.50
once/day4
Raloxifene – generic 60 mg tabs 60 mg PO 46.50
Evista (Lilly) once ...
The FDA has approved elacestrant (Orserdu –
Stemline), an oral estrogen receptor antagonist, for
treatment of estrogen receptor (ER)-positive, human
epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor 1 (ESR1)-mutated advanced or
metastatic breast cancer in postmenopausal women
or men who had disease progression following
endocrine therapy. Elacestrant is the first oral selective
estrogen receptor degrader (SERD) to be approved
for treatment of breast cancer; the injectable SERD
fulvestrant (Faslodex, and generics) was approved
more than 20 years...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):38-40 doi:10.58347/tml.2023.1671d | Show Introduction Hide Introduction
Drugs for Hypothyroidism
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
to increased
gastric pH
Monitor thyroid function
Raloxifene Decreased LT4 effect Probably decreased ...
Primary hypothyroidism is usually the result of
Hashimoto's (autoimmune) thyroiditis, thyroidectomy,
or radioactive iodine therapy. Treatment of
hypothyroidism with replacement doses of thyroid
hormone is usually lifelong. Levothyroxine (LT4;
synthetic thyroxine; Synthroid, and others) is the drug
of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9 doi:10.58347/tml.2023.1670a | Show Introduction Hide Introduction
Drugs for Thyroid Disorders
Treatment Guidelines from The Medical Letter • Aug 01, 2009 (Issue 84)
hormone concentrations reliable than FT4
Raloxifene Decreased LT4 effect Probably decreased Single well ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.